FI935396L - Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta - Google Patents

Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta Download PDF

Info

Publication number
FI935396L
FI935396L FI935396A FI935396A FI935396L FI 935396 L FI935396 L FI 935396L FI 935396 A FI935396 A FI 935396A FI 935396 A FI935396 A FI 935396A FI 935396 L FI935396 L FI 935396L
Authority
FI
Finland
Prior art keywords
molecular weight
high molecular
compositions containing
contrast agent
containing high
Prior art date
Application number
FI935396A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935396A7 (fi
FI935396A0 (fi
Inventor
George C Na
Natarajan Rajagopalan
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of FI935396A0 publication Critical patent/FI935396A0/fi
Publication of FI935396A7 publication Critical patent/FI935396A7/fi
Publication of FI935396L publication Critical patent/FI935396L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI935396A 1992-12-17 1993-12-02 Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta FI935396L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,909 US5326552A (en) 1992-12-17 1992-12-17 Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants

Publications (3)

Publication Number Publication Date
FI935396A0 FI935396A0 (fi) 1993-12-02
FI935396A7 FI935396A7 (fi) 1994-06-18
FI935396L true FI935396L (fi) 1994-06-18

Family

ID=25537712

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935396A FI935396L (fi) 1992-12-17 1993-12-02 Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta

Country Status (17)

Country Link
US (2) US5326552A (enExample)
EP (1) EP0602700A3 (enExample)
JP (1) JPH06192131A (enExample)
KR (1) KR940013544A (enExample)
AU (1) AU664115B2 (enExample)
CA (1) CA2107165A1 (enExample)
CZ (1) CZ266893A3 (enExample)
FI (1) FI935396L (enExample)
HU (1) HUT67265A (enExample)
IL (1) IL107875A0 (enExample)
MX (1) MX9306012A (enExample)
MY (1) MY109875A (enExample)
NO (1) NO934425L (enExample)
NZ (1) NZ248727A (enExample)
PH (1) PH30158A (enExample)
SK (1) SK142793A3 (enExample)
TW (1) TW240171B (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5368837A (en) * 1994-04-14 1994-11-29 Sterling Winthrop Inc. X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US5525327A (en) * 1994-04-14 1996-06-11 Sterling Winthrop Inc. Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5962380A (en) * 1995-06-06 1999-10-05 Chevron Chemical Company Llc Fluorocarbon elastomer compatibility improving agent having wear inhibition effect
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
AU743917B2 (en) * 1996-08-22 2002-02-07 Rtp Pharma Corporation Compositions comprising microparticles of water-insoluble substances
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
GB9705340D0 (en) * 1997-03-14 1997-04-30 Nycomed Imaging As Compositions
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
GB9712981D0 (en) * 1997-06-19 1997-08-27 Nycomed Imaging As Compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
AU761205B2 (en) 1998-03-30 2003-05-29 Skyepharma Canada Inc. Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
AU770645B2 (en) * 1998-11-02 2004-02-26 Alkermes Pharma Ireland Limited Multiparticulate modified release composition
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
BR9915738A (pt) 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
US6309596B1 (en) * 1998-12-15 2001-10-30 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
IL148685A0 (en) * 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2451161A1 (en) * 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
US7687053B2 (en) * 2001-08-20 2010-03-30 Boston Scientific Scimed, Inc. Embolic compositions with non-cyanoacrylate rheology modifying agents
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2003066021A2 (en) * 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003224808A1 (en) * 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
AU2003230885A1 (en) 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040018242A1 (en) * 2002-05-06 2004-01-29 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2488498A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
AU2003257791A1 (en) * 2002-08-15 2004-03-29 Tong Liu Soild nano pharmaceutical formulation and preparation method thereof
EP1553927B9 (en) 2002-09-11 2011-09-21 Elan Pharma International Limited Gel-stabilized nanoparticulate active agent compositions
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ES2431520T3 (es) 2003-01-25 2013-11-26 Seno Medical Instruments, Inc. Procedimiento de formación de imágenes optoacústicas de contraste elevado utilizando nanopartículas no esféricas
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
EP1651189B1 (en) * 2003-08-08 2008-12-03 Elan Pharma International Limited Novel metaxalone compositions
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1772156A1 (en) * 2004-07-21 2007-04-11 Konica Minolta Medical & Graphic, Inc. Liposome-containing x-ray radiopaque dye and process for producing the same
JP5176320B2 (ja) * 2004-08-11 2013-04-03 コニカミノルタエムジー株式会社 リポソーム含有製剤の製造方法
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
KR20070116581A (ko) * 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
WO2006074218A2 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
US8158153B2 (en) * 2005-03-17 2012-04-17 Alkermes Pharma Ireland Limited Nanoparticulate bisphosphonate compositions
JP2008534509A (ja) * 2005-03-23 2008-08-28 エラン ファーマ インターナショナル リミテッド ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
EA200702216A1 (ru) * 2005-04-12 2008-08-29 Элан Фарма Интернэшнл Лимитед Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
EP1888037A2 (en) * 2005-05-10 2008-02-20 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
KR20080026109A (ko) * 2005-05-16 2008-03-24 엘란 파마 인터내셔널 리미티드 세팔로스포린을 함유하는 나노입자형 조절 방출 조성물
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CA2610448A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
WO2007053197A2 (en) * 2005-06-03 2007-05-10 Elan Pharma International, Limited Nanoparticulate acetaminophen formulations
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
DE602006010070D1 (de) * 2005-06-09 2009-12-10 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
EP1898911A1 (en) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
EP1937217A2 (en) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
AU2007256983A1 (en) * 2006-05-30 2007-12-13 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20110311457A1 (en) * 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
JP6072539B2 (ja) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
US9150811B2 (en) 2010-03-31 2015-10-06 Cherron Oronite Company LLC Method for improving copper corrosion performance
US8901050B2 (en) 2010-03-31 2014-12-02 Chevron Oronite Company Llc Method for improving copper corrosion performance
US8993496B2 (en) 2010-03-31 2015-03-31 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US8933001B2 (en) 2010-03-31 2015-01-13 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US8716202B2 (en) 2010-12-14 2014-05-06 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
EP2873670A1 (en) 2013-11-14 2015-05-20 Bayer Pharma Aktiengesellschaft Bis azainositol zirconium complexes for X-ray imaging
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE4015741A1 (de) * 1990-05-16 1991-11-21 Metallgesellschaft Ag Verfahren zur herstellung von mg(pfeil abwaerts)2(pfeil abwaerts)si enthaltenden legierungen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization

Also Published As

Publication number Publication date
MX9306012A (es) 1995-01-31
FI935396A7 (fi) 1994-06-18
PH30158A (en) 1997-01-21
US5326552A (en) 1994-07-05
AU664115B2 (en) 1995-11-02
HU9303490D0 (en) 1994-04-28
AU4867293A (en) 1994-06-30
KR940013544A (ko) 1994-07-15
HUT67265A (en) 1995-03-28
TW240171B (enExample) 1995-02-11
EP0602700A3 (en) 1994-12-21
US5447710A (en) 1995-09-05
SK142793A3 (en) 1994-07-06
JPH06192131A (ja) 1994-07-12
NO934425D0 (no) 1993-12-06
CA2107165A1 (en) 1994-06-18
NO934425L (no) 1994-06-20
MY109875A (en) 1997-09-30
EP0602700A2 (en) 1994-06-22
CZ266893A3 (en) 1994-08-17
FI935396A0 (fi) 1993-12-02
IL107875A0 (en) 1994-04-12
NZ248727A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
FI935396A7 (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
FI932565A7 (fi) Sampookoostumuksia, jotka sisältävät silikoneihin ja kationisiin orgaa nisiin polymeereihin pohjautuvia konditiontiaineita
FI932564A7 (fi) Sampookoostumuksia, jotka sisältävät silikoneihin ja kationisiin pinta -aktiivisiin aineisiin pohjautuvia konditiointiaineita
ATE172477T1 (de) Oligomere, ihre verwendungen sowie formulierungen
DE69113810D1 (de) (poly)sulfid enthaltende polycitraconimide und polyitaconimide.
FI935386A7 (fi) Röntgenvarjoaine
FI934961A7 (fi) Veteen itsestään dispergoituvat, organopolysiloksaania sisältävät koostumukset
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
IT8948696A0 (it) Composizione orale antibatterica, antiplacca, antitartaro
IT8219908A0 (it) Derivati di ferro biodisponibile esenti da gastrolesivita',procedimento di preparazione e relative composizioni farmaceutiche.
FR2597476B1 (fr) Composes benzylideniques, compositions les contenant et agents absorbant le rayonnement ultraviolet constitues par ces composes.
ITMI911155A1 (it) Perfluoropolieteri ad elevata viscosita' e basso contenuto di ossigeno perossidico, e procedimento per la loro preparazione
DE69119249D1 (de) Schnell vulkanisierbare extrudierbare Organosiloxanmassen
DE69003121D1 (de) Filmbildendes Mittel.
KR950701629A (ko) 신규한 탁산 유도체, 그의 제법 및 그를 함유하는 조성물(Novel taxane derivatives, their preparation and compositions containing same)
DE69013796D1 (de) Propylen-Polymer-Zusammensetzung.
FI912017L (fi) Katalytkompositioner.
DE69103427D1 (de) Chemische zusammensetzungen.
DE69100297D1 (de) Katalytische Zusammensetzungen und Polymerisationsverfahren, Hexakiphosphin- und Hexahalid-Verbindungen.
IT1241396B (it) Composizioni tensioattive, loro preparazione e loro impiego come agenti antischiuma. (caso 150-5294)
IT1228437B (it) "derivati di 2,3,4,5,6,7 esaidro 2,7-metano-1,5 benzossazonina (rispettivamente 1,4 benzossazonina), procedimento per la loro preparazione e prodotti medicinali che contengono questi composti.
OA08630A (fr) Fraction immunogène active à l'égard des bilharzioses, sa préparation, compositions immunisantes la contenant.
DE3783937D1 (de) 1,4-naphthochinonderivate enthaltende rodentizide zusammensetzungen.
FI870461A7 (fi) Tartuntaelin.
IT1297199B1 (it) Composizioni stabilizzanti per la lavorazione delle materie polimere.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NANOSYSTEMS L.L.C.

GB Transfer or assigment of application

Owner name: NANOSYSTEMS L.L.C.

FD Application lapsed